Epcoritamab, Glofitamab, and the Future of Lymphoma at ASH 2024

Julio Chavez, MD, MS, associate member in the Lymphoma Section of the Department of Malignant Hematology at Moffitt Cancer Center, discusses some of the important studies and research being presented at the 2024 American Society of Hematology Annual Meeting and Exposition.

Transcription:

0:09 | I think there are a few studies out there. One of the most important ones is the mosunetuzumab [Lunsumio] and polatuzumab [Polivy]and glofitamab [Columvi] and polatuzumab, which are also long-term follow-up. I think it kind of sets the stage that combining bispecific antibodies is probably the way to go for aggressive large B-cell lymphoma. That is one.

0:31 | The other is the real-life experience. Now we have large, retrospective studies looking at the use of epcoritamab and glofitimab after their approvals. These studies are not just from other centers, but also from Moffitt, which led one of the studies. There are also a few studies in Europe showing that the efficacy of bispecific antibodies seems to be similar to the pivotal studies. I think this is valuable because it sends the message to the community oncology field that these drugs work even in real-world settings after approval.

1:20 | We also have more data now for minimal residual disease assessment in lymphoma, looking at how impactful these treatments can be on survival and how we can improve that. There were a few presentations today about adding medications to improve the depth of response, which correlates with better survival. So I think that is something remarkable. A novel class of agents for lymphomas, which I’m particularly interested in, are the cell-mocks—immunology drugs that are available for lymphomas and myeloma. These are more like second- or third-generation drugs with greater efficacy, even in patients who didn’t respond to [chimeric antigen receptor (CAR)] T or bispecifics. So, I think the field is moving in the right direction, and we will have more of these treatments available in the future.